1Epidemiology and Genetics Unit, Department of Health Sciences, York Hospital NHS Trust, York, UK.
Arch Dis Child Fetal Neonatal Ed. 2011 Jul;96(4):F301-4. doi: 10.1136/adc.2009.175851. Epub 2010 Jul 21.
Historically, the investigation of a neonate at risk of Rhesus D antigen (RhD)-associated haemolytic disease has included a direct antiglobulin test on umbilical cord blood. However, the introduction of routine antenatal anti-RhD prophylaxis has led to a significant number of false positive results and recent studies suggest that a positive cord blood direct antiglobulin test is poorly predictive of subsequent hyperbilirubinaemia. The British Committee for Standards in Haematology guidelines now recommend that a direct antiglobulin test should no longer be performed routinely on umbilical cord blood in infants born to RhD-negative mothers. We review the recent changes in antenatal management of RhD-negative mothers and their impact on the neonatal presentation of RhD-associated haemolytic disease of the newborn that underpin this recommendation. We conclude that there is convincing evidence to support the guidelines. Finally, we consider how babies born to RhD-negative mothers should be investigated and consider alternative strategies to detect neonatal hyperbilirubinaemia.
从历史上看,对有发生 RhD 抗原(RhD)相关溶血病风险的新生儿的检查包括脐带血直接抗球蛋白试验。然而,常规产前抗 RhD 预防措施的引入导致了大量假阳性结果,最近的研究表明,脐带血直接抗球蛋白试验阳性对随后的高胆红素血症的预测性很差。英国血液学标准委员会指南现在建议,对于 RhD 阴性母亲所生的婴儿,不再常规在脐带血中进行直接抗球蛋白试验。我们回顾了 RhD 阴性母亲产前管理的最新变化及其对 RhD 相关新生儿溶血病新生儿表现的影响,这为该建议提供了依据。我们的结论是,有令人信服的证据支持这些指南。最后,我们考虑 RhD 阴性母亲所生的婴儿应如何进行检查,并考虑替代策略来检测新生儿高胆红素血症。